4.4 Article

Prevalence, Correlates, and Treatment of Lifetime Suicidal Behavior Among Adolescents Results From the National Comorbidity Survey Replication Adolescent Supplement

Journal

JAMA PSYCHIATRY
Volume 70, Issue 3, Pages 300-310

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/2013.jamapsychiatry.55

Keywords

-

Categories

Funding

  1. Analysis Group
  2. Bristol-Myers Squibb
  3. Eli Lilly and Co
  4. EPI-Q
  5. GlaxoSmithKline
  6. Johnson & Johnson Pharmaceuticals
  7. Ortho-McNeil Janssen Scientific Affairs
  8. Pfizer Inc
  9. sanofi-aventis
  10. Shire US Inc.
  11. National Institute of Mental Health [U01-MH60220, R01-MH66627, U01MH060220-09S1, K01-MH092526, K01-MH085710, R01-MH070884, R13-MH066849, R01-MH069864, R01-MH077883]
  12. National Institute on Drug Abuse, the Substance Abuse and Mental Health Services Administration
  13. Robert Wood Johnson Foundation [044780]
  14. John W. Alden Trust
  15. National Institute on Drug Abuse [R01-DA016558]
  16. Fogarty International Center of the National Institutes of Health [FIRCA R03-TW006481]
  17. John D. and Catherine T. MacArthur Foundation
  18. Pfizer Foundation
  19. Pan American Health Organization
  20. AstraZeneca
  21. Ortho-McNeil
  22. Pfizer
  23. Wyeth

Ask authors/readers for more resources

Context: Although suicide is the third leading cause of death among US adolescents, little is known about the prevalence, correlates, or treatment of its immediate precursors, adolescent suicidal behaviors (ie, suicide ideation, plans, and attempts). Objectives: To estimate the lifetime prevalence of suicidal behaviors among US adolescents and the associations of retrospectively reported, temporally primary DSM-IV disorders with the subsequent onset of suicidal behaviors. Design: Dual-frame national sample of adolescents from the National Comorbidity Survey Replication Adolescent Supplement. Setting: Face-to-face household interviews with adolescents and questionnaires for parents. Participants: A total of 6483 adolescents 13 to 18 years of age and their parents. Main Outcome Measures: Lifetime suicide ideation, plans, and attempts. Results: The estimated lifetime prevalences of suicide ideation, plans, and attempts among the respondents are 12.1%, 4.0%, and 4.1%, respectively. The vast majority of adolescents with these behaviors meet lifetime criteria for at least one DSM-IV mental disorder assessed in the survey. Most temporally primary (based on retrospective age-of-onset reports) fear/anger, distress, disruptive behavior, and substance disorders significantly predict elevated odds of subsequent suicidal behaviors in bivariate models. The most consistently significant associations of these disorders are with suicide ideation, although a number of disorders are also predictors of plans and both planned and unplanned attempts among ideators. Most suicidal adolescents (>80%) receive some form of mental health treatment. In most cases (<55%), treatment starts prior to onset of suicidal behaviors but fails to prevent these behaviors from occurring. Conclusions: Suicidal behaviors are common among US adolescents, with rates that approach those of adults. The vast majority of youth with suicidal behaviors have preexisting mental disorders. The disorders most powerfully predicting ideation, though, are different from those most powerfully predicting conditional transitions from ideation to plans and attempts. These differences suggest that distinct prediction and prevention strategies are needed for ideation, plans among ideators, planned attempts, and unplanned attempts. JAMA Psychiatry. 2013;70(3):300-310. Published online January 9, 2013. doi:10.1001/2013.jamapsychiatry.55

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available